Treatment of laryngopharyngeal and lingual hereditary angioedema with bradykinin-B2-receptor-antagonist icatibant

被引：0

|

作者：

Bas, M.

Greve, J.

Kojda, G.

Bier, H.

Hoffmann, K.

机构：

[1] Univ Hosp Dusseldorf, Dusseldorf, Germany

[2] Univ Hosp Dusseldorf, Inst Pharmacol & Clin Pharmacol, Dusseldorf, Germany

来源：

ALLERGY | 2007年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

引用

收藏

页码：95 / 95

页数：1

相关论文

共 50 条

[21] The efficacy and safety of Icatibant, a selective bradykinin B2 receptor antagonist, for treating the symptoms of hereditary angioedema attacks
Cicardi, M.
ALLERGY, 2008, 63 : 474 - 474
[22] First use of icatibant (selective bradykinin receptor antagonist) in hereditary angioedema patients in the UK
Karanam, S.
Demptser, J.
Longhurst, H.
Gompels, M.
CLINICAL AND EXPERIMENTAL ALLERGY, 2009, 39 (12): : 1943 - 1943
[23] Successful treatment of hereditary angioedema with a bradykinin receptor antagonist
Bork, K
Meng, G
Wiest, K
Grundt, B
Schneiders, V
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 123 (02)
[24] Self-administration of a novel subcutaneous bradykinin b2 receptor antagonist, icatibant, as an effective treatment option in patients with hereditary angioedema
Santucci S.
Pham H.
Harrison R.
Yang W.
Allergy, Asthma & Clinical Immunology, 10 (Suppl 2)
[25] Successful treatment of ACE inhibitor-induced angioedema with icatibant, a bradykinin B2 receptor antagonist
Pucar, Phillippa A.
O'Sullivan, Michael
Goudie, Adrian
Marr, Timothy
Brusch, Anna
MEDICAL JOURNAL OF AUSTRALIA, 2015, 202 (11) : 596 - 597
[26] Repeated hereditary angioedema attacks can be effectively treated with the selective, potent bradykinin B2 receptor antagonist Icatibant
Aberer, W.
ALLERGY, 2008, 63 : 474 - 474
[27] Icatibant, a selective bradykinin B2 receptor antagonist, effective and safe in treating the symptoms of hereditary angioedema (HAE) attacks
Riedl, M.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S103 - S103
[28] Resolution of symptoms in a patient with Hereditary Angioedema (HAE) following treatment with icatibant, a potent and selective Bradykinin-2 receptor antagonist
Boehm, T.
Lumry, W. R.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (01) : S279 - S279
[29] Treatment of hereditary angioedema due to C1 inhibitor deficiency with Icatibant, a selective bradykinin B2 receptor antagonist: a safety perspective
Bork, K.
ALLERGY, 2008, 63 : 47 - 47
[30] Successful treatment of 103 attacks of hereditary hngioedema (HAE) with bradykinin B2 receptor antagonist icatibant
Malbran, A.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S102 - S102

← 1 2 3 4 5 →